Trump hints at Affordable Care Act replacement as Dr. Oz outlines healthcare reform plans emphasizing consumer choice and ...

Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ...

Investing.com -- Novo Nordisk ’s CEO Mike Doustdar said Monday that the company’s agreement with the White House to reduce prices on its popular weight-loss drugs is designed to expand access through ...

Wegovy-maker Novo Nordisk's CEO said on Monday a deal with the White House to slash prices on its popular weight‑loss drugs ...

Trump deals with Eli Lilly and Novo Nordisk increase access to obesity drugs, providing a safe, convenient way to slim down ...

Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks? Investors will be watching what Trump makes happen.

A dramatic corporate governance battle reached its climax at Novo Nordisk on Friday when the company's majority shareholder forced a complete boardroom overh ...

Scholar Rock soared by 24.41 percent on Friday to close at $37.41 apiece as investor sentiment was boosted by the progress of ...

Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

Europe’s day saw major moves in trade, UK tax policy, a BBC apology to Trump, and big board changes at Novo Nordisk.